Abstract:Abstract Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Half of the total HCC-related deaths and new cases occurred in China. Different from many cancers, HCC is intrinsically resistant to conventional chemotherapies, and many attempts to develop new systemic agents for HCC have failed in clinic. Lack of clinically relevant and genetically well-defined preclinical models critically accounts for the failures. In this study, we established an extensive panel of Chinese HCC patient-derived xenograft (PDX) models by directly transplanting surgically resected patient tumor tissues in BALB/c nude or SCID mice. Implantation of 254 patient samples resulted in 70 transplantable PDX models (27.6%) covering stage I, II, III, and IV tumors. Xenograft tissues could be serially passaged, cryopreserved, and revived with a success rate of over 94%. Early passages between p2-p4 of PDX tissues were used in the histological and molecular characterization. The histology of PDX tissues recapitulated the features of the original samples and maintained the heterogeneity of human tumors. Unsupervised hierarchical cluster analysis of gene expression profiles in 7 paired samples assessed by GeneChip® PrimeView™ Human Gene Expression Array revealed that PDX tumor tissues retained the global gene-expression patterns of patient samples. Using next-generation sequencing we performed exome sequencing of 43 of PDX models. Contaminated murine DNA reads were removed by a proprietary algorithm to eliminate homology bias. A wide variety of SNPs were identified and some may represent driver mutations, such as ones on JAK1 and JAK2 genes. Copy number variation analysis by Genome-Wide Human SNP Array 6.0 in 24 PDX models elucidated amplifications of a number of genes, including MET, AKT2, AKT3, mTOR, ALDH1A1, ALDH1A2, JUN and NOV. In vivo efficacy studies exhibited differential responses to standard-of-care compounds in the models. Collectively, with the current intense interest in development of targeted therapies, the use of patient liver cancer tissue-derived models with well genomic characterization provides an excellent, and perhaps more relevant, platform for preclinical studies of experimental therapeutics, and for biomarker discovery and translational research. Citation Format: Douglas D. Fang, Qiang Xu, Yexiong Tan, Lei Chen, Hongye Sun, Qingyang Gu, Bin Zhang, Qin Luo, Shu-hui Chen, Hongyang Wang, Chi-Chung Chan. Genetic characterization of an extensive panel of patient-derived xenograft tumor models of hepatocellular carcinoma for preclinical development. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2739. doi:10.1158/1538-7445.AM2013-2739

Gastric Cancer Assembloids Derived from Patient‐Derived Xenografts: A Preclinical Model for Therapeutic Drug Screening (Small Methods 9/2024)

Gastric Cancer Assembloids Derived from Patient-Derived Xenografts: A Preclinical Model for Therapeutic Drug Screening

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Patient-Derived Xenograft: A More Standard "Avatar" Model in Preclinical Studies of Gastric Cancer

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Gastric cancer patient-derived organoids model for the therapeutic drug screening

Personalized Primary Tumor Xenograft Model Established for the Pre-Clinical Trial to Guide Postoperative Chemotherapy

Xenograft and organoid models in developing precision medicine for gastric cancer (Review)

A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments

Characterization and Validation of Potential Therapeutic Targets Based on the Molecular Signature of Patient-Derived Xenografts in Gastric Cancer

Establishment and Characterization of Patient-Derived Tumor Xenograft Using Gastroscopic Biopsies in Gastric Cancer

IDDF2022-ABS-0105 Patient-derived Organoids Can Predict Chemotherapy Response of Gastric Cancers and Analysis of Its Molecular Characteristics

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Patient-derived tumor-like cell clusters for drug testing in cancer therapy

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening

Establishment and Genomic Characterizations of Patient-Derived Esophageal Squamous Cell Carcinoma Xenograft Models Using Biopsies for Treatment Optimization

Genomic Characterization of a Large Panel of Patient-Derived Hepatocellular Carcinoma Xenograft Tumor Models for Preclinical Development

Abstract 105: Establishment of Imaging-Based Orthotopic Tumor Models for Pharmacological Evaluation of Anticancer Agents

Abstract 2739: Genetic Characterization of an Extensive Panel of Patient-Derived Xenograft Tumor Models of Hepatocellular Carcinoma for Preclinical Development.